Strategic partnership struck over auto-injector to treat anaphylactic shock

Rx Bandz and Weiss-Aug has announced a strategic partnership to manufacture and supply commercial quantities of Rx Bandz’s MiniJect epinephrine auto-injector for the treatment of anaphylactic shock. 

Weiss-Aug will manufacture the MiniJect as Rx Bandz moves towards completing its regulatory submission for FDA approval of the combination therapeutic and delivery device.  Once FDA approval is obtained, Weiss-Aug will scale up production of the MiniJect.

The MiniJect is a device that a patient administers in emergency medical conditions, such as anaphylactic shock due to an allergic reaction to food or an insect sting. The MiniJect also offers portability, temperature resistance and other safety features that make it highly attractive for patients. Rx Bandz's auto-injector represents a platform technology capable of delivering many other therapeutics to treat multiple emergency conditions such as hypoglycemia, epilepsy, opioid overdose and chemical weapons exposure.

Jessica Walsh, Rx Bandz’s CEO and founder, said: “We at Rx Bandz could not be happier and prouder to work with Weiss-Aug as our manufacturing and supply partner. WeissAug is a world-wide leader in precision manufacturing and shares the same commitment to excellence and quality that we have at Rx Bandz.”

Ken Beller, vice president of sales & marketing at Weiss-Aug, added: “The opportunity to work on this exciting auto-injector technology appealed to us. We pride ourselves on our ability to work on novel and innovative products that meet the most exacting standards for a wide variety of clients across the globe in the fields of medical, automotive and industrial technology.”